Correlation Between Inhibrx and Nuvalent
Can any of the company-specific risk be diversified away by investing in both Inhibrx and Nuvalent at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibrx and Nuvalent into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibrx and Nuvalent, you can compare the effects of market volatilities on Inhibrx and Nuvalent and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibrx with a short position of Nuvalent. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibrx and Nuvalent.
Diversification Opportunities for Inhibrx and Nuvalent
Very weak diversification
The 3 months correlation between Inhibrx and Nuvalent is 0.52. Overlapping area represents the amount of risk that can be diversified away by holding Inhibrx and Nuvalent in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Nuvalent and Inhibrx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibrx are associated (or correlated) with Nuvalent. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Nuvalent has no effect on the direction of Inhibrx i.e., Inhibrx and Nuvalent go up and down completely randomly.
Pair Corralation between Inhibrx and Nuvalent
Given the investment horizon of 90 days Inhibrx is expected to generate 1.21 times more return on investment than Nuvalent. However, Inhibrx is 1.21 times more volatile than Nuvalent. It trades about -0.09 of its potential returns per unit of risk. Nuvalent is currently generating about -0.13 per unit of risk. If you would invest 1,486 in Inhibrx on October 26, 2024 and sell it today you would lose (184.00) from holding Inhibrx or give up 12.38% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Inhibrx vs. Nuvalent
Performance |
| Timeline |
| Inhibrx |
| Nuvalent |
Inhibrx and Nuvalent Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inhibrx and Nuvalent
The main advantage of trading using opposite Inhibrx and Nuvalent positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibrx position performs unexpectedly, Nuvalent can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nuvalent will offset losses from the drop in Nuvalent's long position.| Inhibrx vs. Crinetics Pharmaceuticals | Inhibrx vs. Merus BV | Inhibrx vs. Lyell Immunopharma | Inhibrx vs. Kronos Bio |
| Nuvalent vs. Arcellx | Nuvalent vs. Vaxcyte | Nuvalent vs. Viridian Therapeutics | Nuvalent vs. Ventyx Biosciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Complementary Tools
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| CEOs Directory Screen CEOs from public companies around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |